Mechanistic exploratory endpoint analyses warrant cautious interpretation: Dupilumab showed a non-significant trend toward higher conjunctivitis risk [RR = 2.01(0.29–13.77)], potentially aligning with IL-4/IL-13 pathway inhibition theory, though current evidence remains insufficient to establish causality or exclude random variation. Here, IL4 is linked to conjunctivitis.